Commentary on Hey and Kimmelman

Hu F Rosenberger WF . The theory of response-adaptive randomization in clinical trials. Hoboken, NJ: John Wiley & Sons, Inc., 2006.

Korn EL Freidlin B . Outcome-adaptive randomization: is it useful? J Clin Oncol 2011; 29: 771–776.

Lee JJ Chen N Yin G . Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res 2012; 18: 4498–4507.

Du Y Wang X Lee JJ . Simulation study for evaluating the performance of response-adaptive randomization. Contemp Clin Trials 2014; 40C: 15–25.

Berry DA Eick SG . Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 1995; 14: 231–246.

Cheng Y Berry DA . Optimal adaptive randomized designs for clinical trials. Biometrika 2007; 94: 673–687.

Lee JJ Gu X Liu S . Bayesian adaptive randomization designs for targeted agent development. Clin Trials 2010; 7: 584–596.

Lai TL Lavori PW Shih M-CI . Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 2012; 9: 141–154.

Wason JMS Trippa L . A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014; 33: 2206–2221.

Rosenberger WF Sverdlov O Hu F . Adaptive randomization for clinical trials. J Biopharm Stat 2012; 22: 719–736.

Lee JJ Feng L . Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 2005; 23: 4450–4457.

Wu W Shi Q Sargent DJ . Statistical considerations for the next generation of clinical trials. Semin Oncol 2011; 38: 598–604.

Rubin EH Gilliland DG . Drug development and clinical trials—the path to an approved cancer drug. Nat Rev Clin Oncol 2012; 9: 215–222.

Qin R Kohli M . Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Pers Med 2013; 10: 859–869.

La Thangue NB Kerr DJ . Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011; 8: 587–596.

Devita VT Eggermont AMM Hellman S . Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol 2014; 11: 663–669.

Gajewski BJ Berry SM Quintana M . Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Stat Med, Epub ahead of print 7 January 2015. 10.1002/sim.6403

Marshall E . Does the moral philosophy of the Belmont Report rest on a mistake? IRB 1986; 8: 5–6.

Chevret S . Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med 2012; 31: 1002–1013.

Lee JJ Chu CT . Bayesian clinical trials in action. Stat Med 2012; 31: 2955–2972.

The University of Texas MD Anderson Cancer Center, Division of Quantitative Sciences—Department of Biostatistics. Software download site, https://biostatistics.mdanderson.org/SoftwareDownload/ (accessed 8 December 2014).

Kim ES Herbst RS Wistuba II . The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44–53.